Brookfield Asst Financials
This page shows Brookfield Asst (BAM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
High-margin cash generation remains intact, but much larger assets and leverage now support roughly the same earnings engine.
Between FY2023 and FY2025, net income changed little, rising only from$2.1B to$2.4B . Total assets reached$17.0B by FY2025 while return on assets settled at14.1% , which implies the company is now generating similar profits from a much larger asset base rather than from a leaner balance sheet.
Cash conversion has been improving: operating cash flow rose from about
The revenue line does not appear working-capital heavy: FY2025 accounts receivable were only
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Brookfield Asst's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Brookfield Asst's revenue surged 21.0% year-over-year to $4.8B, reflecting rapid business expansion. This strong growth earns a score of 48/100.
Brookfield Asst carries a low D/E ratio of 0.76, meaning only $0.76 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 87/100, indicating a strong balance sheet with room for future borrowing.
Brookfield Asst earns a strong 26.9% return on equity (ROE), meaning it generates $27 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100. This is up from 24.1% the prior year.
Brookfield Asst passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Brookfield Asst generates $0.88 in operating cash flow ($2.1B OCF vs $2.4B net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Key Financial Metrics
Earnings & Revenue
Brookfield Asst generated $4.8B in revenue in fiscal year 2025. This represents an increase of 21.0% from the prior year.
Brookfield Asst reported $2.4B in net income in fiscal year 2025. This represents an increase of 13.8% from the prior year.
Cash & Balance Sheet
Brookfield Asst held $1.6B in cash against $0 in long-term debt as of fiscal year 2025.
Margins & Returns
Brookfield Asst's net profit margin was 49.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 3.2 percentage points from the prior year.
Brookfield Asst's ROE was 26.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 2.8 percentage points from the prior year.
Capital Allocation
Brookfield Asst spent $412.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
BAM Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B+11.3% | $1.3B+14.9% | $1.1B+0.8% | $1.1B+1.7% | $1.1B-4.8% | $1.1B+21.9% | $916.0M+3.6% | $884.0M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $9.0M-60.9% | $23.0M+27.8% | $18.0M+200.0% | $6.0M-72.7% | $22.0M+10.0% | $20.0M+53.8% | $13.0M+44.4% | $9.0M |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | $33.0M+65.0% | $20.0M-35.5% | $31.0M+933.3% | $3.0M-57.1% | $7.0M-12.5% | $8.0M+166.7% | $3.0M-25.0% | $4.0M |
| Income Tax | $299.0M+283.3% | $78.0M+4.0% | $75.0M0.0% | $75.0M-41.9% | $129.0M+34.4% | $96.0M-32.4% | $142.0M+100.0% | $71.0M |
| Net Income | $615.0M-11.1% | $692.0M+18.5% | $584.0M+15.2% | $507.0M-25.4% | $680.0M+26.6% | $537.0M+3.7% | $518.0M+38.9% | $373.0M |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BAM Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $17.0B+3.2% | $16.5B+2.3% | $16.1B+7.9% | $15.0B+5.7% | $14.2B | N/A | $4.2B | N/A |
| Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $1.6B+49.1% | $1.1B+121.2% | $480.0M+44.6% | $332.0M-17.8% | $404.0M-55.3% | $903.0M+8930.0% | $10.0M-99.6% | $2.6B |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $106.0M | N/A | N/A | N/A | $225.0M | N/A | N/A | N/A |
| Goodwill | $236.0M | N/A | N/A | N/A | $251.0M | N/A | N/A | N/A |
| Total Liabilities | $6.7B+15.2% | $5.8B+14.4% | $5.1B+25.5% | $4.1B+37.3% | $3.0B | N/A | $925.0M | N/A |
| Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $8.9B+5.3% | $8.5B-0.1% | $8.5B-0.2% | $8.5B-3.0% | $8.8B-2.8% | $9.0B+178.8% | $3.2B-64.2% | $9.0B |
| Retained Earnings | -$851.0M-20.9% | -$704.0M+1.5% | -$715.0M-15.9% | -$617.0M-26.4% | -$488.0M | N/A | -$119.0M | N/A |
BAM Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $706.0M-5.2% | $745.0M+40.8% | $529.0M+99.6% | $265.0M+94.9% | $136.0M-76.0% | $567.0M+44.3% | $393.0M-23.8% | $516.0M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$76.0M-850.0% | -$8.0M+98.4% | -$490.0M-683.3% | $84.0M+127.0% | $37.0M+102.8% | -$1.3B-192.7% | -$452.0M-7433.3% | -$6.0M |
| Financing Cash Flow | -$108.0M+32.9% | -$161.0M-249.1% | $108.0M+125.6% | -$422.0M+36.0% | -$659.0M-137.9% | -$277.0M+54.1% | -$603.0M-4.0% | -$580.0M |
| Dividends Paid | $703.0M-0.4% | $706.0M+0.6% | $702.0M-0.7% | $707.0M+14.2% | $619.0M-0.2% | $620.0M+0.2% | $619.0M-0.2% | $620.0M |
| Share Buybacks | $227.0M+229.0% | $69.0M | $0-100.0% | $116.0M | $0 | $0 | $0 | $0 |
BAM Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | 44.1%-11.1pp | 55.3%+1.7pp | 53.6%+6.7pp | 46.9%-17.1pp | 64.0%+15.9pp | 48.1%-8.5pp | 56.5%+14.4pp | 42.2% |
| Return on Equity | 6.9%-1.3pp | 8.2%+1.3pp | 6.9%+0.9pp | 6.0%-1.8pp | 7.8%+1.8pp | 6.0%-10.1pp | 16.0%+11.9pp | 4.1% |
| Return on Assets | 3.6%-0.6pp | 4.2%+0.6pp | 3.6%+0.2pp | 3.4%-1.4pp | 4.8% | N/A | 12.4% | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt-to-Equity | 0.76+0.1 | 0.69+0.1 | 0.60+0.1 | 0.48+0.1 | 0.34 | N/A | 0.29 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Brookfield Asst's annual revenue?
Brookfield Asst (BAM) reported $4.8B in total revenue for fiscal year 2025. This represents a 21.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Brookfield Asst's revenue growing?
Brookfield Asst (BAM) revenue grew by 21% year-over-year, from $4.0B to $4.8B in fiscal year 2025.
Is Brookfield Asst profitable?
Yes, Brookfield Asst (BAM) reported a net income of $2.4B in fiscal year 2025, with a net profit margin of 49.8%.
What is Brookfield Asst's net profit margin?
Brookfield Asst (BAM) had a net profit margin of 49.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Brookfield Asst's return on equity (ROE)?
Brookfield Asst (BAM) has a return on equity of 26.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Brookfield Asst's operating cash flow?
Brookfield Asst (BAM) generated $2.1B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Brookfield Asst's total assets?
Brookfield Asst (BAM) had $17.0B in total assets as of fiscal year 2025, including both current and long-term assets.
What is Brookfield Asst's debt-to-equity ratio?
Brookfield Asst (BAM) had a debt-to-equity ratio of 0.76 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Brookfield Asst's return on assets (ROA)?
Brookfield Asst (BAM) had a return on assets of 14.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Brookfield Asst's Piotroski F-Score?
Brookfield Asst (BAM) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Brookfield Asst's earnings high quality?
Brookfield Asst (BAM) has an earnings quality ratio of 0.88x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Brookfield Asst?
Brookfield Asst (BAM) scores 39 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.